ID   RPMI-8226
AC   CVCL_0014
AS   CVCL_7353
SY   RPMI 8226; RPMI.8226; RPMI8226; RPMI no. 8226; RPMI no 8226; RPMI #8226; 8226; RPMI 8226/S; RPMI-8226S; RPMI8226/S; 8226/S; Roswell Park Memorial Institute 8226; GM02132; GM2132; GM 2132; GM02132C; Simpson
DR   BTO; BTO:0000726
DR   CLO; CLO_0008873
DR   CLO; CLO_0031845
DR   EFO; EFO_0002322
DR   MCCL; MCC:0000406
DR   CLDB; cl4182
DR   CLDB; cl4183
DR   CLDB; cl4184
DR   CLDB; cl5252
DR   AddexBio; C0003002/62
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   ArrayExpress; E-TABM-937
DR   ATCC; CCL-155
DR   ATCC; CRM-CCL-155
DR   BCRC; 60384
DR   BioSample; SAMN03471458
DR   BioSample; SAMN03472934
DR   BioSample; SAMN03473581
DR   BioSample; SAMN10988318
DR   CCLE; RPMI8226_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR   CCRID; 3111C0001CCC000083
DR   Cell_Model_Passport; SIDM00087
DR   CGH-DB; 9162-4
DR   ChEMBL-Cells; CHEMBL3307732
DR   ChEMBL-Targets; CHEMBL614882
DR   CLS; 300431/p771_RPMI_8226
DR   Coriell; GM02132
DR   Cosmic; 720773
DR   Cosmic; 724856
DR   Cosmic; 742952
DR   Cosmic; 759915
DR   Cosmic; 760397
DR   Cosmic; 875867
DR   Cosmic; 886084
DR   Cosmic; 888018
DR   Cosmic; 897452
DR   Cosmic; 905964
DR   Cosmic; 919145
DR   Cosmic; 974250
DR   Cosmic; 991554
DR   Cosmic; 999791
DR   Cosmic; 1044255
DR   Cosmic; 1092628
DR   Cosmic; 1139509
DR   Cosmic; 1139639
DR   Cosmic; 1175858
DR   Cosmic; 1305340
DR   Cosmic; 1312326
DR   Cosmic; 1762461
DR   Cosmic; 1998470
DR   Cosmic; 2081405
DR   Cosmic; 2159574
DR   Cosmic; 2367260
DR   Cosmic; 2391801
DR   Cosmic-CLP; 905964
DR   DepMap; ACH-000817
DR   DSMZ; ACC-402
DR   ECACC; 87012702
DR   ENCODE; ENCBS457ZNO
DR   ENCODE; ENCBS604KZU
DR   GDSC; 905964
DR   GEO; GSM2135
DR   GEO; GSM50198
DR   GEO; GSM50261
DR   GEO; GSM143340
DR   GEO; GSM290304
DR   GEO; GSM562819
DR   GEO; GSM621590
DR   GEO; GSM750813
DR   GEO; GSM799349
DR   GEO; GSM799412
DR   GEO; GSM887548
DR   GEO; GSM888631
DR   GEO; GSM1153419
DR   GEO; GSM1181289
DR   GEO; GSM1181334
DR   GEO; GSM1199922
DR   GEO; GSM1199923
DR   GEO; GSM1199924
DR   GEO; GSM1199925
DR   GEO; GSM1199926
DR   GEO; GSM1199927
DR   GEO; GSM1374855
DR   GEO; GSM1666389
DR   GEO; GSM1670389
DR   GEO; GSM2124680
DR   IARC_TP53; 360
DR   IARC_TP53; 27232
DR   IGRhCellID; RPMI8226
DR   IZSLER; BS TCL 92
DR   JCRB; IFO50013
DR   JCRB; JCRB0034
DR   KCLB; 10155
DR   LiGeA; CCLE_817
DR   LINCS_LDP; LCL-2049
DR   Lonza; 61
DR   NCBI_Iran; C210
DR   NCI-DTP; RPMI-8226
DR   PharmacoDB; RPMI8226_1327_2019
DR   PRIDE; PXD001276
DR   PRIDE; PXD005942
DR   RCB; RCB3010
DR   SKY/M-FISH/CGH; 2743
DR   TKG; TKG 0243
DR   Wikidata; Q54951245
RX   CelloPub=CLPUB00447;
RX   DOI=10.1007/978-1-4757-1647-4_11;
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   DOI=10.1016/B978-0-12-427150-0.50135-2;
RX   PubMed=2041050;
RX   PubMed=2140233;
RX   PubMed=2537114;
RX   PubMed=3893568;
RX   PubMed=4177524;
RX   PubMed=4366935;
RX   PubMed=5243066;
RX   PubMed=6042436;
RX   PubMed=8943038;
RX   PubMed=9290701;
RX   PubMed=9510473;
RX   PubMed=10087940;
RX   PubMed=10557056;
RX   PubMed=10583232;
RX   PubMed=10700174;
RX   PubMed=10936422;
RX   PubMed=11154231;
RX   PubMed=11157491;
RX   PubMed=12068308;
RX   PubMed=14555701;
RX   PubMed=15215163;
RX   PubMed=15748285;
RX   PubMed=16956823;
RX   PubMed=17088437;
RX   PubMed=17171682;
RX   PubMed=18277095;
RX   PubMed=18605421;
RX   PubMed=18647998;
RX   PubMed=18700954;
RX   PubMed=19306352;
RX   PubMed=19372543;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=21173094;
RX   PubMed=22384151;
RX   PubMed=22460905;
RX   PubMed=22628656;
RX   PubMed=23074853;
RX   PubMed=23856246;
RX   PubMed=23933261;
RX   PubMed=24279929;
RX   PubMed=24670534;
RX   PubMed=25485619;
RX   PubMed=25688540;
RX   PubMed=25984343;
RX   PubMed=27377824;
RX   PubMed=27397505;
RX   PubMed=27807467;
RX   PubMed=28196595;
RX   PubMed=29718670;
RX   PubMed=30285677;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
WW   https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW   https://strap.nci.nih.gov/celline_detail.php?sample_id=33
WW   http://www.proteinatlas.org/learn/cellines
WW   http://tcpaportal.org/mclp/
WW   http://www.cellresource.cn/fdetail.aspx?id=83
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI-60 cancer cell line panel.
CC   Part of: NCI-7 clinical proteomics reference material cell line panel.
CC   Characteristics: Produces IgG lambda.
CC   Doubling time: 60 hours (PubMed=25984343); 33.5 hours (NCI-DTP); ~60-70 hours (DSMZ).
CC   HLA typing: A*30:01,68:02; B*15:03,15:10; C*02:02:04,03:04:02; DPB1*01:01:02,13:01; DQB1*02:01,02:02; DRB1*03:01:01,07:01 (PubMed=15748285).
CC   HLA typing: A*30,68:02; B*15,15; C*02:02,03:04 (Direct_author_submission).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Heterozygous for EGFR p.Thr751Ile (c.2252C>T) (PubMed=17088437).
CC   Sequence variation: Heterozygous for KRAS p.Gly12Ala (c.35G>C) (PubMed=11157491; PubMed=12068308; PubMed=17088437).
CC   Sequence variation: Homozygous for TP53 p.Glu285Lys (c.853G>A); temperature-sensitive (PubMed=17088437; PubMed=18277095).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep antibody staining analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Fluorescence phenotype profiling.
CC   Omics: lncRNA expression profiling.
CC   Omics: Metabolome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=73.94%; Native American=0%; East Asian, North=1.06%; East Asian, South=0%; South Asian=0%; European, North=11.76%; European, South=13.24% (PubMed=30894373).
CC   Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C.
CC   Misspelling: RPMI-8266; Occasionally.
CC   Misspelling: RPMI-8826; In Cosmic 875867.
CC   Derived from sampling site: Peripheral blood.
ST   Source(s): AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; ECACC; JCRB; KCLB; PubMed=19372543; PubMed=25877200; TKG
ST   Amelogenin: X,Y (AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; ECACC; JCRB; KCLB; PubMed=25877200)
ST   Amelogenin: X (PubMed=19372543; TKG)
ST   CSF1PO: 12
ST   D13S317: 11
ST   D16S539: 9
ST   D18S51: 15,19
ST   D19S433: 13.2,14
ST   D21S11: 28,29
ST   D2S1338: 20
ST   D3S1358: 16,17
ST   D5S818: 11,13 (AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; ECACC; JCRB; KCLB; PubMed=19372543; TKG)
ST   D5S818: 13 (PubMed=25877200)
ST   D7S820: 9,10
ST   D8S1179: 12,13 (CCRID)
ST   D8S1179: 13 (CLS; PubMed=25877200)
ST   FGA: 19
ST   Penta D: 2.2,11
ST   Penta E: 16,17
ST   TH01: 8
ST   TPOX: 8,11
ST   vWA: 16,18 (AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; ECACC; JCRB; KCLB; PubMed=19372543; PubMed=25877200; TKG)
ST   vWA: 16 (DSMZ)
DI   NCIt; C3242; Plasma cell myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   61Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 31
//
RX   CelloPub=CLPUB00447;
RA   Mulivor R.A., Suchy S.F.;
RT   "1992/1993 catalog of cell lines. NIGMS human genetic mutant cell
RT   repository. 16th edition. October 1992.";
RL   (In) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda (1992).
//
RX   DOI=10.1007/978-1-4757-1647-4_11;
RA   Moore G.E.;
RT   "Cell lines from humans with hematopoietic malignancies.";
RL   (In) Human tumor cells in vitro; Fogh J. (eds.); pp.299-331; Springer; New York (1975).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   DOI=10.1016/B978-0-12-427150-0.50135-2;
RA   Matsuoka Y.;
RT   "Immunoglobulins.";
RL   (In) Tissue culture. Methods and applications; Kruse P.F. Jr., Patterson M.K. Jr. (eds); pp.599-607, Academic Press; New York (1973).
//
RX   PubMed=2041050; DOI=10.1093/jnci/83.11.757;
RA   Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K., Vistica D.T.,
RA   Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M.,
RA   Campbell H., Mayo J., Boyd M.;
RT   "Feasibility of a high-flux anticancer drug screen using a diverse
RT   panel of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 83:757-766(1991).
//
RX   PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x;
RA   Nakano A., Harada T., Morikawa S., Kato Y.;
RT   "Expression of leukocyte common antigen (CD45) on various human
RT   leukemia/lymphoma cell lines.";
RL   Acta Pathol. Jpn. 40:107-115(1990).
//
RX   PubMed=2537114;
RA   Duperray C., Klein B., Durie B.G.M., Zhang X., Jourdan M.,
RA   Poncelet P., Favier F., Vincent C., Brochier J., Lenoir G.M.,
RA   Bataille R.;
RT   "Phenotypic analysis of human myeloma cell lines.";
RL   Blood 73:566-572(1989).
//
RX   PubMed=3893568;
RA   Goldstein M., Hoxie J., Zembryki D., Matthews D., Levinson A.I.;
RT   "Phenotypic and functional analysis of B cell lines from patients with
RT   multiple myeloma.";
RL   Blood 66:444-446(1985).
//
RX   PubMed=4177524;
RA   Matsuoka Y., Takahashi M., Yagi Y., Moore G.E., Pressman D.;
RT   "Synthesis and secretion of immunoglobulins by established cell lines
RT   of human hematopoietic origin.";
RL   J. Immunol. 101:1111-1120(1968).
//
RX   PubMed=4366935;
RA   Minowada J., Nonoyama M., Moore G.E., Rauch A.M., Pagano J.S.;
RT   "The presence of the Epstein-Barr viral genome in human lymphoblastoid
RT   B-cell lines and its absence in a myeloma cell line.";
RL   Cancer Res. 34:1898-1903(1974).
//
RX   PubMed=5243066;
RA   Moore G.E., Kitamura H.;
RT   "Cell line derived from patient with myeloma.";
RL   N. Y. State J. Med. 68:2054-2060(1968).
//
RX   PubMed=6042436; DOI=10.3181/00379727-125-32327;
RA   Matsuoka Y., Moore G.E., Yagi Y., Pressman D.;
RT   "Production of free light chains of immunoglobulin by a hematopoietic
RT   cell line derived from a patient with multiple myeloma.";
RL   Proc. Soc. Exp. Biol. Med. 125:1246-1250(1967).
//
RX   PubMed=8943038; DOI=10.1073/pnas.93.24.13931;
RA   Bergsagel P.L., Chesi M., Nardini E., Brents L.A., Kirby S.L.,
RA   Kuehl W.M.;
RT   "Promiscuous translocations into immunoglobulin heavy chain switch
RT   regions in multiple myeloma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:13931-13936(1996).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x;
RA   Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y.,
RA   Hirai H.;
RT   "Frameshift mutations of the hMSH6 gene in human leukemia cell
RT   lines.";
RL   Jpn. J. Cancer Res. 89:33-39(1998).
//
RX   PubMed=10087940; DOI=10.1016/S0165-4608(98)00157-5;
RA   Kuipers J., Vaandrager J.W., Weghuis D.O., Pearson P.L., Scheres J.,
RA   Lokhorst H.M., Clevers H., Bast B.J.E.G.;
RT   "Fluorescence in situ hybridization analysis shows the frequent
RT   occurrence of 14q32.3 rearrangements with involvement of
RT   immunoglobulin switch regions in myeloma cell lines.";
RL   Cancer Genet. Cytogenet. 109:99-107(1999).
//
RX   PubMed=10557056; DOI=10.1038/sj.leu.2401563;
RA   Yoshida S., Nakazawa N., Iida S., Hayami Y., Sato S., Wakita A.,
RA   Shimizu S., Taniwaki M., Ueda R.;
RT   "Detection of MUM1/IRF4-IgH fusion in multiple myeloma.";
RL   Leukemia 13:1812-1816(1999).
//
RX   PubMed=10583232; DOI=10.1046/j.1365-2141.1999.01705.x;
RA   Puthier D., Derenne S., Barille S., Moreau P., Harousseau J.-L.,
RA   Bataille R., Amiot M.;
RT   "Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells.";
RL   Br. J. Haematol. 107:392-395(1999).
//
RX   PubMed=10700174; DOI=10.1038/73432;
RA   Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T.,
RA   Iyer V., Jeffrey S.S., van de Rijn M., Waltham M., Pergamenschikov A.,
RA   Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N.,
RA   Botstein D., Brown P.O.;
RT   "Systematic variation in gene expression patterns in human cancer cell
RT   lines.";
RL   Nat. Genet. 24:227-235(2000).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=11154231; DOI=10.1182/blood.v97.2.516;
RA   Hjertner O., Hjorth-Hansen H., Borset M., Seidel C., Waage A.,
RA   Sundan A.;
RT   "Bone morphogenetic protein-4 inhibits proliferation and induces
RT   apoptosis of multiple myeloma cells.";
RL   Blood 97:516-522(2001).
//
RX   PubMed=11157491; DOI=10.1182/blood.V97.3.729;
RA   Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A.,
RA   Kuehl W.M., Bergsagel P.L.;
RT   "Activated fibroblast growth factor receptor 3 is an oncogene that
RT   contributes to tumor progression in multiple myeloma.";
RL   Blood 97:729-736(2001).
//
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
//
RX   PubMed=14555701;
RA   Shammas M.A., Shmookler Reis R.J., Akiyama M., Koley H., Chauhan D.,
RA   Hideshima T., Goyal R.K., Hurley L.H., Anderson K.C., Munshi N.C.;
RT   "Telomerase inhibition and cell growth arrest by G-quadruplex
RT   interactive agent in multiple myeloma.";
RL   Mol. Cancer Ther. 2:825-833(2003).
//
RX   PubMed=15215163; DOI=10.1016/S0002-9440(10)63276-2;
RA   Inoue J., Otsuki T., Hirasawa A., Imoto I., Matsuo Y., Shimizu S.,
RA   Taniwaki M., Inazawa J.;
RT   "Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be
RT   associated with drug-resistance phenotype in multiple myeloma.";
RL   Am. J. Pathol. 165:71-81(2004).
//
RX   PubMed=15748285; DOI=10.1186/1479-5876-3-11;
RA   Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L.,
RA   Morse H.C. III, Stroncek D., Marincola F.M.;
RT   "HLA class I and II genotype of the NCI-60 cell lines.";
RL   J. Transl. Med. 3:11-11(2005).
//
RX   PubMed=16956823;
RA   Bataille R., Jego G., Robillard N., Barille-Nion S., Harousseau J.-L.,
RA   Moreau P., Amiot M., Pellat-Deceunynck C.;
RT   "The phenotype of normal, reactive and malignant plasma cells.
RT   Identification of 'many and multiple myelomas' and of new targets for
RT   myeloma therapy.";
RL   Haematologica 91:1234-1240(2006).
//
RX   PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433;
RA   Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C.,
RA   O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L.,
RA   Buck G., Butler A., Clements J., Cole J., Dicks E., Forbes S.,
RA   Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C.,
RA   Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A.,
RA   Mironenko T., Parker A., Perry J., Raine K., Richardson D.,
RA   Shepherd R., Small A., Smith R., Solomon H., Stephens P., Teague J.W.,
RA   Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.;
RT   "Mutation analysis of 24 known cancer genes in the NCI-60 cell line
RT   set.";
RL   Mol. Cancer Ther. 5:2606-2612(2006).
//
RX   PubMed=17171682; DOI=10.1002/gcc.20404;
RA   Lombardi L., Poretti G., Mattioli M., Fabris S., Agnelli L.,
RA   Bicciato S., Kwee I., Rinaldi A., Ronchetti D., Verdelli D.,
RA   Lambertenghi-Deliliers G., Bertoni F., Neri A.;
RT   "Molecular characterization of human multiple myeloma cell lines by
RT   integrative genomics: insights into the biology of the disease.";
RL   Genes Chromosomes Cancer 46:226-238(2007).
//
RX   PubMed=18277095; DOI=10.4161/cbt.7.5.5712;
RA   Berglind H., Pawitan Y., Kato S., Ishioka C., Soussi T.;
RT   "Analysis of p53 mutation status in human cancer cell lines: a
RT   paradigm for cell line cross-contamination.";
RL   Cancer Biol. Ther. 7:699-708(2008).
//
RX   PubMed=18605421; DOI=10.1093/jnci/45.5.951;
RA   Ikeuchi T., Sandberg A.A.;
RT   "Chromosome pulverization in virus-induced heterokaryons of mammalian
RT   cells from different species.";
RL   J. Natl. Cancer Inst. 45:951-963(1970).
//
RX   PubMed=18647998; DOI=10.1093/jncimonographs/lgn011;
RA   Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.;
RT   "Characterization of MYC translocations in multiple myeloma cell
RT   lines.";
RL   J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
//
RX   PubMed=18700954; DOI=10.1186/1755-8794-1-37;
RA   Ronchetti D., Lionetti M., Mosca L., Agnelli L., Andronache A.,
RA   Fabris S., Deliliers G.L., Neri A.;
RT   "An integrative genomic approach reveals coordinated expression of
RT   intronic miR-335, miR-342, and miR-561 with deregulated host genes in
RT   multiple myeloma.";
RL   BMC Med. Genomics 1:37-37(2008).
//
RX   PubMed=19306352; DOI=10.1002/gcc.20660;
RA   Lionetti M., Agnelli L., Mosca L., Fabris S., Andronache A.,
RA   Todoerti K., Ronchetti D., Deliliers G.L., Neri A.;
RT   "Integrative high-resolution microarray analysis of human myeloma cell
RT   lines reveals deregulated miRNA expression associated with allelic
RT   imbalances and gene expression profiles.";
RL   Genes Chromosomes Cancer 48:521-531(2009).
//
RX   PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921;
RA   Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y.,
RA   Chanock S.J., Weinstein J.N.;
RT   "DNA fingerprinting of the NCI-60 cell line panel.";
RL   Mol. Cancer Ther. 8:713-724(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21173094; DOI=10.3324/haematol.2010.033456;
RA   Moreaux J., Klein B., Bataille R., Descamps G., Maiga S., Hose D.,
RA   Goldschmidt H., Jauch A., Reme T., Jourdan M., Amiot M.,
RA   Pellat-Deceunynck C.;
RT   "A high-risk signature for patients with multiple myeloma established
RT   from the molecular classification of human myeloma cell lines.";
RL   Haematologica 96:574-582(2011).
//
RX   PubMed=22384151; DOI=10.1371/journal.pone.0032096;
RA   Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H.,
RA   Yoon C.N., Chang Y.-T.;
RT   "Identification of cancer cell-line origins using fluorescence
RT   image-based phenomic screening.";
RL   PLoS ONE 7:E32096-E32096(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22628656; DOI=10.1126/science.1218595;
RA   Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L.,
RA   Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.;
RT   "Metabolite profiling identifies a key role for glycine in rapid
RT   cancer cell proliferation.";
RL   Science 336:1040-1044(2012).
//
RX   PubMed=23074853; DOI=10.1134/S1990519X12050136;
RA   Turilova V.K., Smirnova T.D.;
RT   "Karyotypic variability of human myeloma cell lines.";
RL   Tsitologiia 54:621-636(2012).
//
RX   PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342;
RA   Abaan O.D., Polley E.C., Davis S.R., Zhu Y.J., Bilke S., Walker R.L.,
RA   Pineda M., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L.,
RA   Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.;
RT   "The exomes of the NCI-60 panel: a genomic resource for cancer biology
RT   and systems pharmacology.";
RL   Cancer Res. 73:4372-4382(2013).
//
RX   PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018;
RA   Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M.,
RA   Kuster B.;
RT   "Global proteome analysis of the NCI-60 cell line panel.";
RL   Cell Rep. 4:609-620(2013).
//
RX   PubMed=24279929; DOI=10.1186/2049-3002-1-20;
RA   Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R.,
RA   Hirshfield K.M., Oltvai Z.N., Vazquez A.;
RT   "The metabolic demands of cancer cells are coupled to their size and
RT   protein synthesis rates.";
RL   Cancer Metab. 1:20-20(2013).
//
RX   PubMed=24670534; DOI=10.1371/journal.pone.0092047;
RA   Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.;
RT   "High resolution copy number variation data in the NCI-60 cancer cell
RT   lines from whole genome microarrays accessible through CellMiner.";
RL   PLoS ONE 9:E92047-E92047(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25688540; DOI=10.1002/cyto.a.22643;
RA   Maiga S., Brosseau C., Descamps G., Dousset C., Gomez-Bougie P.,
RA   Chiron D., Menoret E., Kervoelen C., Vie H., Cesbron A.,
RA   Moreau-Aubry A., Amiot M., Pellat-Deceunynck C.;
RT   "A simple flow cytometry-based barcode for routine authentication of
RT   multiple myeloma and mantle cell lymphoma cell lines.";
RL   Cytometry A 87:285-288(2015).
//
RX   PubMed=25984343; DOI=10.1038/sdata.2014.35;
RA   Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S.,
RA   East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H.,
RA   Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M.,
RA   Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S.,
RA   Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D.,
RA   Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C.,
RA   Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P.,
RA   Golub T.R., Root D.E., Hahn W.C.;
RT   "Parallel genome-scale loss of function screens in 216 cancer cell
RT   lines for the identification of context-specific genetic
RT   dependencies.";
RL   Sci. Data 1:140035-140035(2014).
//
RX   PubMed=27377824; DOI=10.1038/sdata.2016.52;
RA   Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J.,
RA   Vandesompele J.;
RT   "Long non-coding RNA expression profiling in the NCI60 cancer cell
RT   line panel using high-throughput RT-qPCR.";
RL   Sci. Data 3:160052-160052(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27807467; DOI=10.1186/s13100-016-0078-4;
RA   Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J.,
RA   Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.;
RT   "A map of mobile DNA insertions in the NCI-60 human cancer cell
RT   panel.";
RL   Mob. DNA 7:20-20(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P.,
RA   Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29718670; DOI=10.1021/acs.jproteome.8b00165;
RA   Clark D.J., Hu Y., Bocik W., Chen L., Schnaubelt M., Roberts R.,
RA   Shah P., Whiteley G., Zhang H.;
RT   "Evaluation of NCI-7 cell line panel as a reference material for
RT   clinical proteomics.";
RL   J. Proteome Res. 18:2205-2215(2018).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940-940(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//